Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lanabecestat on Warfarin PK in Healthy Subjects
NCT02540668Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lanabecestat in Alzheimer's disease (AD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Concentration of Unbound S-Warfarin at 144 hours and Area Under the Concentration Curve 0-∞ of Unbound S-Warfarin at 144 hours. Started Sep 2015; status: completed.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02540668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540668.